{"transactions":[{"id":4634009,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":110.04,"value":11004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."}],"balance_after":53609,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4634008,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":109.569,"value":120525.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":53709,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4634007,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3300,"price":108.454,"value":357898.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54809,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4634006,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":730,"price":107.168,"value":78232.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58109,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4621732,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":108.991,"value":435964.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58839,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4621731,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":8896,"price":108.04,"value":961123.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":62839,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4621730,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":106.828,"value":320484.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":71735,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4621729,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":3100,"price":106.132,"value":329009.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":74735,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":730564,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:14:12.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001543792-26-000002","document":"wk-form4_1782159249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000154379226000002/wk-form4_1782159249.xml","form_type":"4"}},{"id":788730,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-07T23:04:36.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":6040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":6040,"derivative":{"exercise_price":65.87,"expiration_date":"2036-05-05","underlying":"Common Stock","underlying_shares":6040},"source":{"system":"sec-edgar","filing":"0001159036-26-000064","document":"wk-form4_1778195074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000064/wk-form4_1778195074.xml","form_type":"4"}},{"id":788729,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T23:04:36.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":3796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":77835,"source":{"system":"sec-edgar","filing":"0001159036-26-000064","document":"wk-form4_1778195074.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000064/wk-form4_1778195074.xml","form_type":"4"}},{"id":1101740,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:37:28.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000063","document":"wk-form4_1750883840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000063/wk-form4_1750883840.xml","form_type":"4"}},{"id":1161483,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2025-05-02T20:11:14.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":5750,"derivative":{"exercise_price":60.03,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":5750},"source":{"system":"sec-edgar","filing":"0001415889-25-011777","document":"form4-05022025_080510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925011777/form4-05022025_080510.xml","form_type":"4"}},{"id":1161482,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T20:11:14.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":4165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.   Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person following completion of service as a director."}],"balance_after":74039,"source":{"system":"sec-edgar","filing":"0001415889-25-011777","document":"form4-05022025_080510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925011777/form4-05022025_080510.xml","form_type":"4"}},{"id":1434008,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:57:27.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":9881,"price":57.7,"value":570133.7,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director."}],"balance_after":69874,"source":{"system":"sec-edgar","filing":"0001415889-24-021305","document":"form4-08142024_080823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021305/form4-08142024_080823.xml","form_type":"4"}},{"id":1434007,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:57:27.000Z","date":"2024-08-13","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":56.193,"value":561930.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $56.058 to $56.26.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director."}],"balance_after":79755,"source":{"system":"sec-edgar","filing":"0001415889-24-021305","document":"form4-08142024_080823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021305/form4-08142024_080823.xml","form_type":"4"}},{"id":1434006,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:57:27.000Z","date":"2024-08-12","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":55.723,"value":557230.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $55.70 to $55.825.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director."}],"balance_after":89755,"source":{"system":"sec-edgar","filing":"0001415889-24-021305","document":"form4-08142024_080823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021305/form4-08142024_080823.xml","form_type":"4"}},{"id":1477407,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:03:52.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000045","document":"wk-form4_1718658225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000045/wk-form4_1718658225.xml","form_type":"4"}},{"id":1481029,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T20:15:42.000Z","date":"2024-06-12","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":50.619,"value":506190.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $50.50 to $50.935.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":99755,"source":{"system":"sec-edgar","filing":"0001415889-24-016672","document":"form4-06132024_080638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924016672/form4-06132024_080638.xml","form_type":"4"}},{"id":1481028,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T20:15:42.000Z","date":"2024-06-11","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":50.011,"value":500110.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $50.00 to $50.21.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":109755,"source":{"system":"sec-edgar","filing":"0001415889-24-016672","document":"form4-06132024_080638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924016672/form4-06132024_080638.xml","form_type":"4"}},{"id":1533938,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-04-29T22:11:03.000Z","date":"2024-04-25","kind":"grant","planned":false,"acquired":true,"shares":8804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":8804,"derivative":{"exercise_price":38.46,"expiration_date":"2034-04-25","underlying":"Common Stock","underlying_shares":8804},"source":{"system":"sec-edgar","filing":"0001415889-24-011705","document":"form4-04292024_100445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011705/form4-04292024_100445.xml","form_type":"4"}},{"id":1533937,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-29T22:11:03.000Z","date":"2024-04-25","kind":"grant","planned":false,"acquired":true,"shares":6501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.   Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":119755,"source":{"system":"sec-edgar","filing":"0001415889-24-011705","document":"form4-04292024_100445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011705/form4-04292024_100445.xml","form_type":"4"}},{"id":1852486,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:52:47.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000062","document":"wf-form4_168695955711451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000062/wf-form4_168695955711451.xml","form_type":"4"}},{"id":1858392,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-06-12T21:28:05.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date."}],"balance_after":95000,"derivative":{"exercise_price":0.5,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-23-036403","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919123036403/doc4.xml","form_type":"4"}},{"id":1866277,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T22:20:54.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service.  Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025."}],"balance_after":158215,"source":{"system":"sec-edgar","filing":"0001209191-23-034582","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919123034582/doc4.xml","form_type":"4"}},{"id":1899772,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-05-09T22:27:10.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":11371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":11371,"derivative":{"exercise_price":31,"exercise_date":"2024-05-05","expiration_date":"2033-05-05","underlying":"Common Stock","underlying_shares":11371},"source":{"system":"sec-edgar","filing":"0001415889-23-007694","document":"form4-05092023_100504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007694/form4-05092023_100504.xml","form_type":"4"}},{"id":1899771,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-09T22:27:10.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":8065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.   Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":113254,"source":{"system":"sec-edgar","filing":"0001415889-23-007694","document":"form4-05092023_100504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007694/form4-05092023_100504.xml","form_type":"4"}},{"id":2094746,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-07T00:07:45.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":10000,"price":56.118,"value":561180.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.10 to $56.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":105189,"source":{"system":"sec-edgar","filing":"0001415889-22-012142","document":"form4-12072022_121235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588922012142/form4-12072022_121235.xml","form_type":"4"}},{"id":2094745,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-07T00:07:45.000Z","date":"2022-12-05","kind":"sale","acquired":false,"shares":10000,"price":55.737,"value":557370.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $55.70 to $55.83.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":115189,"source":{"system":"sec-edgar","filing":"0001415889-22-012142","document":"form4-12072022_121235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588922012142/form4-12072022_121235.xml","form_type":"4"}},{"id":2094744,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-07T00:07:45.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":10000,"price":58.8,"value":588000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $58.80 to $58.83.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":125189,"source":{"system":"sec-edgar","filing":"0001415889-22-012142","document":"form4-12072022_121235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588922012142/form4-12072022_121235.xml","form_type":"4"}},{"id":2230111,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:04:15.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000071","document":"wf-form4_165542423007735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000071/wf-form4_165542423007735.xml","form_type":"4"}},{"id":2233697,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T21:41:05.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date."}],"balance_after":95000,"derivative":{"exercise_price":1,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-22-036425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919122036425/doc4.xml","form_type":"4"}},{"id":2250918,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-01T00:11:02.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":26480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service.  The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2023."}],"balance_after":122501,"source":{"system":"sec-edgar","filing":"0001209191-22-032989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919122032989/doc4.xml","form_type":"4"}},{"id":2279553,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-07T00:07:58.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":6206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":135189,"source":{"system":"sec-edgar","filing":"0001179110-22-002912","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022002912/edgar.xml","form_type":"4"}},{"id":2490701,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T02:41:03.000Z","date":"2021-12-01","kind":"purchase","acquired":true,"shares":10000,"price":4.4493,"value":44493.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001808805-21-000026","document":"wf-form4_163841284890930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000026/wf-form4_163841284890930.xml","form_type":"4"}},{"id":2490700,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T02:41:03.000Z","date":"2021-12-01","kind":"purchase","acquired":true,"shares":10000,"price":4.4612,"value":44612.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001808805-21-000026","document":"wf-form4_163841284890930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000026/wf-form4_163841284890930.xml","form_type":"4"}},{"id":2490699,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T02:41:03.000Z","date":"2021-12-01","kind":"purchase","acquired":true,"shares":10000,"price":4.5,"value":45000.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001808805-21-000026","document":"wf-form4_163841284890930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000026/wf-form4_163841284890930.xml","form_type":"4"}},{"id":2490698,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T02:41:03.000Z","date":"2021-11-30","kind":"purchase","acquired":true,"shares":20000,"price":4.57,"value":91400.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001808805-21-000026","document":"wf-form4_163841284890930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000026/wf-form4_163841284890930.xml","form_type":"4"}},{"id":2690816,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-29T00:19:20.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":4661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest, and the shares underlying the restricted stock units shall be released to the reporting person, on January 1, 2023, subject to the reporting person's continued service."}],"balance_after":96021,"source":{"system":"sec-edgar","filing":"0001209191-21-036712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919121036712/doc4.xml","form_type":"4"}},{"id":2690815,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-29T00:19:20.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":4497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service.  The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2022."}],"balance_after":91360,"source":{"system":"sec-edgar","filing":"0001209191-21-036712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919121036712/doc4.xml","form_type":"4"}},{"id":2725298,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-05-07T00:04:18.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":5230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":128983,"source":{"system":"sec-edgar","filing":"0001179110-21-004974","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911021004974/edgar.xml","form_type":"4"}},{"id":2845556,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T23:13:59.000Z","date":"2021-02-17","kind":"purchase","acquired":true,"shares":62500,"price":16,"value":1000000.0,"ownership":{"direct":true},"balance_after":62500,"source":{"system":"sec-edgar","filing":"0001209191-21-012515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919121012515/doc4.xml","form_type":"4"}},{"id":2907956,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-13T21:21:38.000Z","date":"2021-01-11","kind":"purchase","acquired":true,"shares":33898,"price":29.5,"value":999991.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities were purchased by the reporting person in an underwritten public offering completed by the Issuer on January 11, 2021."}],"balance_after":86863,"source":{"system":"sec-edgar","filing":"0001209191-21-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919121003423/doc4.xml","form_type":"4"}},{"id":3103985,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-19T20:19:48.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. All of the restricted stock units shall vest in a single installment on June 17, 2021, subject to the reporting person's continued service through the earlier to occur of (i) June 17, 2021 or (ii) the date of the issuer's 2021 Annual Meeting of Stockholders."}],"balance_after":52965,"source":{"system":"sec-edgar","filing":"0001209191-20-037920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919120037920/doc4.xml","form_type":"4"}},{"id":3165561,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock","published_at":"2020-05-01T23:15:57.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":8829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":123753,"source":{"system":"sec-edgar","filing":"0001179110-20-005382","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020005382/edgar.xml","form_type":"4"}},{"id":3165027,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-01T20:24:52.000Z","date":"2020-04-29","kind":"exercise","acquired":false,"shares":9702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.94,"expiration_date":"2026-09-21","underlying":"Common Stock","underlying_shares":9702},"source":{"system":"sec-edgar","filing":"0001209191-20-026533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919120026533/doc4.xml","form_type":"4"}},{"id":3165026,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T20:24:52.000Z","date":"2020-04-29","kind":"exercise","acquired":true,"shares":9702,"price":6.94,"value":67331.88,"ownership":{"direct":true},"balance_after":44965,"source":{"system":"sec-edgar","filing":"0001209191-20-026533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919120026533/doc4.xml","form_type":"4"}},{"id":3294613,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-03T21:15:03.000Z","date":"2020-01-30","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units issued pursuant to the issuer's Amended and Restated 2010 Stock Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, all of the restricted stock units shall vest in a single installment on the date of the 2020 annual meeting of the stockholders of the issuer."}],"balance_after":35263,"source":{"system":"sec-edgar","filing":"0001209191-20-005995","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919120005995/doc4.xml","form_type":"4"}},{"id":3321598,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-01-03T21:10:21.000Z","date":"2019-12-31","kind":"exercise","acquired":false,"shares":15994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on\nDecember 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on\nDecember 31, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15994},"source":{"system":"sec-edgar","filing":"0001209191-20-000821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919120000821/doc4.xml","form_type":"4"}},{"id":3321597,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T21:10:21.000Z","date":"2019-12-31","kind":"exercise","acquired":true,"shares":15994,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":29263,"source":{"system":"sec-edgar","filing":"0001209191-20-000821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000120919120000821/doc4.xml","form_type":"4"}},{"id":3540220,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-03T20:23:59.000Z","date":"2019-05-02","kind":"grant","acquired":true,"shares":12173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2020 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":114924,"source":{"system":"sec-edgar","filing":"0001179110-19-005511","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019005511/edgar.xml","form_type":"4"}},{"id":3949892,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-02T23:42:37.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":10363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2019 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":102751,"source":{"system":"sec-edgar","filing":"0001179110-18-006091","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018006091/edgar.xml","form_type":"4"}},{"id":4331842,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-05T20:59:40.000Z","date":"2017-05-04","kind":"grant","acquired":true,"shares":14135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 4, 2018 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":92388,"source":{"system":"sec-edgar","filing":"0001179110-17-006704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017006704/edgar.xml","form_type":"4"}}]}